References
- Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics—2018 update: A report from the American Heart Association. Circulation. 2018; 137(12):e67–e492. DOI: 10.1161/CIR.0000000000000558
- World Health Organization. WHO clinical treatment guideline for tobacco cessation in adults. World Health Organization; Jul 2024. 53 p. Available from:
https://www.who.int/publications/i/item/9789240096431 . - Dalmau R, Alanazi AM, Arora M, Banerjee A, Bianco E, Gaalema DE, et al. A complex interplay: Navigating the crossroads of tobacco use, cardiovascular disease, and the COVID-19 pandemic: A WHF policy brief. Global Heart. 2024; 19(1):55. DOI: 10.5334/gh.1334
- Rodgman A, Perfetti TA. The chemical components of tobacco and tobacco smoke. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2009. DOI: 10.1201/9781420078848
- Pryor WA, Stone K. Oxidants in cigarette smoke: Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Annals of New York Academy of Sciences. 1993; 686(1993):12–28. DOI: 10.1111/j.1749-6632.1993.tb39148.x
- Fowles J, Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tobacco Control. 2003; 12(4):424–430. DOI: 10.1136/tc.12.4.424
- Hoffmann D, Hoffmann I. Letters to the Editor – Tobacco smoke components. Beiträge zur Tabakforschung International. 1998; 18(1):49–52. DOI: 10.2478/cttr-2013-0668
- Soleimani F, Dobaradaran S, De-la-Torre GE, Schmidt TC, Saeedi R. Content of toxic components of cigarette, cigarette smoke vs Cigarette Butts: A comprehensive systematic review. Science of the Total Environment. 2022; 813(2022):152667. DOI: 10.1016/j.scitotenv.2021.152667
- Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. Journal of the American College of Cardiology. 2004; 43(10):1731–1737. DOI: 10.1016/j.jacc.2003.12.047
- Smith CJ, Fischer TH. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis. 2001; 158(2):257–267. DOI: 10.1016/s0021-9150(01)00570-6
- Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013; 33(7):1460–1467. DOI: 10.1161/ATVBAHA.112.300154
- Kjeldsen K, Thomsen HK, Astrup P. Effects of carbon monoxide on myocardium: Ultrastructural changes in rabbits after moderate, chronic exposure. Circulation Research. 1974; 34(3):339–348. DOI: 10.1161/01.res.34.3.339
- Zevin S, Saunders S, Gourlay SG, Jacob P, Benowitz NL. Cardiovascular effects of carbon monoxide and cigarette smoking. Journal of the American College of Cardiology. 2001; 38(6):1633–1638. DOI: 10.1016/s0735-1097(01)01616-3
- Sun YP, Zhu BQ, Browne AE, Sievers RE, Bekker JM, Chatterjee K, et al. Nicotine does not influence arterial lipid deposits in rabbits exposed to second-hand smoke. Circulation. 2001; 104(7):810–814. DOI: 10.1161/hc3301.092788
- Svrivastava SK, Barua RS, Saha DC, Eales-Reynolds LJ, DeVoe MC, Ambrose JA. Endogenous free radical generating sources are involved in smoking-mediated dysfunction of nitric oxide biosynthesis in human coronary artery endothelial cells: An in vitro demonstration, Journal of the American College of Cardiology. 2003; 41(6 Supplement 1):306A. DOI: 10.1016/S0735-1097(03)82432-4
- Kayyali US, Budhiraja R, Pennella CM, Cooray S, Lanzillo JJ, Chalkley R, et al. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicology and Applied Pharmacology. 2003; 188(1):59–68. DOI: 10.1016/s0041-008x(02)00076-5
- Meier BM, Shelley D. The fourth pillar of the Framework Convention on Tobacco Control: harm reduction and the international human right to health. Public Health Reports. 2006; 121(5):494–500. DOI: 10.1177/003335490612100503
- Hatsukami DK, Carroll DM. Tobacco harm reduction: Past history, current controversies and a proposed approach for the future. Preventive Medicine. 2020; 140:106099. DOI: 10.1016/j.ypmed.2020.106099
- Congress US.
Family Smoking Prevention and Tobacco Control Act . In Congress US (Ed.) H R 1256 Vol Public Law. Washington, DC: U. S. Government Printing Office; 2009. pp. 111–131. - European Union. Manufacture, presentation and sale of tobacco products [Internet]. EUR-Lex [updated 2014 Jun; cited 2024 Sept]. Available from:
https://eur-lex.europa.eu/EN/legal-content/summary/manufacture-presentation-and-sale-of-tobacco-products.html . - Lee PN, Fry JS, Hamling JS. Investigation into the risk of ultra-low tar cigarettes and lung cancer. Regulatory Toxicology and Pharmacology. 2017; 89(2017):112–117. DOI: 10.1016/j.yrtph.2017.07.023
- National Cancer Institute. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2001 Oct. Available from:
https://cancercontrol.cancer.gov/sites/default/files/2020-08/m13_complete.pdf . - Pope CA
3rd , Burnett RT, Turner MC, Cohen A, Krewski D, Jerrett M, et al. Lung cancer and cardiovascular disease mortality associated with ambient air pollution and cigarette smoke: Shape of the exposure-response relationships. Environmental Health Perspectives. 2011; 119(11):1616–1621. DOI: 10.1289/ehp.1103639 - Lee PN. Tar level of cigarettes smoked and risk of smoking-related diseases. Inhalation Toxicology. 2018; 30(1):5–18. DOI: 10.1080/08958378.2018.1443174
- Hackshaw A, Morris JK, Boniface S, Tang JL, Milenković D. Low cigarette consumption and risk of coronary heart disease and stroke: Meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018; 360:j5855. DOI: 10.113.6/bmj.j5855
- Black HR.
Smoking and cardiovascular disease . In Laragh JH, Brenner BM (Eds.) Hypertension: Pathophysiology, Diagnosis and Management. 2nd edition. New York, NY: Raven Press Ltd.; 1995. pp. 2621–2647. - Clarkson TB, Weingand KW, Kaplan JR, Adams MR. Mechanisms of atherogenesis. Circulation. 1987; 76(1 part 2):20–28.
- Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: An overview of molecular mechanisms. Current Vascular Pharmacology. 2007; 5(4):276–292. DOI: 10.2174/157016107782023406
- Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: An in vitro demonstration in human coronary artery endothelial cells. Circulation. 2003; 107(18):2342–2347. DOI: 10.1161/01.CIR.0000066691.52789.BE
- Kayyali US, Budhiraja R, Pennella CM, Cooray S, Lanzillo JJ, Chalkley R, et al. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicology and Applied Pharmacology. 2003; 188(1):59–68. DOI: 10.1016/s0041-008X(02)00076-5
- Jaimes EA, DeMaster EG, Tian RX, Raij L. Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004; 24(6):1031–1036. DOI: 10.1161/01.ATV.0000127083.88549.58
- Suski JM, Lebiedzinska M, Bonora M, Pinton P, Duszynski J, Wieckowski MR.
Relation between mitochondrial membrane potential and ROS formation . In Palmeira CM, Moreno AJ (Eds.) Mitochondrial Bioenergetics: Methods and Protocols. Totowa, NJ: Humana Press; 2012. pp. 183–205. DOI: 10.1007/978-1-61779-382-0_12 - Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circulation Research. 2002; 91(4):281–291. DOI: 10.1161/01.res.0000029784.15893.10
- Ishida M, Sakai C, Ishida T. Role of DNA damage in the pathogenesis of atherosclerosis. Journal of Cardiology. 2022; 81(4):331–336. DOI: 10.1016/j.jjcc.2022.08.010
- Bouki KP, Katsafados MG, Chatzopoulos DN, Psychari SN, Toutouzas KP, Charalampopoulos AF, et al. Inflammatory markers and plaque morphology: An optical coherence tomography study. International Journal of Cardiology. 2012; 154(3):287–292. DOI: 10.1016/j.ijcard.2010.09.059
- Hawkins RI. Smoking, platelets and thrombosis. Nature. 1972; 236(5348):450–452. DOI: 10.1038/236450a0
- Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. The New England Journal of Medicine. 2023; 389(14):1273–1285. DOI: 10.1056/NEJMoa2206916
- Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. Lancet. 2020; 395(10226):795–808. DOI: 10.1016/S0140-6736(19)32008-2
- Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw Y, Wareham NJ, Khaw KT, et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. European Heart Journal. 2020; 41(11):1190–1199. DOI: 10.1093/eurheartj/ehz239
- Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, Ferrario M, et al. MORGAM (an international pooling of cardiovascular cohorts). International Journal of Epidemiology. 2005; 34(1):21–27. DOI: 10.1093/ije/dyh327
- Duncan MS, Freiberg MS, Greevy, RA
Jr. , Kundu S, Vasan RS, Tindle HA. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA. 2019; 322(7):642–650. DOI: 10.1001/jama.2019.10298 - Walicka M, Krysiński A, La Rosa GRM, Sun A, Campagna D, Di Ciaula A, et al. Influence of quitting smoking on diabetes-related complications: A scoping review with a systematic search strategy. Diabetes & Metabolic Syndrome. 2024; 18(5):103044. DOI: 10.1016/j.dsx.2024.103044
- Jones MR, Barnoya J, Stranges S, Losonczy L, Navas-Acien A. Cardiovascular events following smoke-free legislations: An updated systematic review and meta-analysis. Current Environmental Health Reports. 2014; 1(3):239–249. DOI: 10.1007/s40572-014-0020-1
- Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011; 378(9799):1297–1305. DOI: ttps://doi.org/10.1016/S0140-6736(11)60781-2
- Lan T, Palm KCA, Hoeben L, Benavente ED, Perry RN, Civelek M, et al. Tobacco smoking is associated with sex- and plaque-type specific upregulation of CRLF1 in atherosclerotic lesions. Atherosclerosis. 2024; 397(2024):118554. DOI: 10.1016/j.atherosclerosis.2024.118554
- Campesi I, Carru C, Zinellu A, Occhioni S, Sanna M, Palermo M, et al. Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex-gender specific manner in healthy young humans. American Journal of Translational Research. 2013; 5(5):497–509.
- Tolstrup JS, Hvidtfeldt UA, Flachs EM, Spiegelman D, Heitmann BL, Bälter K, et al. Smoking and risk of coronary heart disease in younger, middle-aged, and older adults. American Journal of Public Health. 2014; 104(1):96–102. DOI: 10.2105/AJPH.2012.301091
- Dimitriadis K, Narkiewicz K, Leontsinis I, Konstantinidis D, Mihas C, Andrikou I, et al. Acute effects of electronic and tobacco cigarette smoking on sympathetic nerve activity and blood pressure in humans. International Journal of Environmental Research and Public Health. 2022; 19(6):3237. DOI: 10.3390/ijerph19063237
- Münzel T, Hahad O, Kuntic M, Keaney JF, Deanfield JE, Daiber A. Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes. European Heart Journal. 2020; 41(41):4057–4070. DOI: 10.1093/eurheartj/ehaa460
- Barkhurdar W, Hussain A, Saqlain M, Zahra R, Hussain I, Saqib M, et al. Smoking behaviour in post-acute myocardial infarction patients: cross-sectional study. Annals of Medicine and Surgery. 2024; 86(5):2531–2537. DOI: 10.1097/MS9.0000000000001333
- Wu X, Zhang H, Qi W, Zhang Y, Li J, Li Z, et al. Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. Cell Death & Disease. 2018; 9(2):171. DOI: 10.1038/s41419-017-0257-3
- Salehi N, Janjani P, Tadbiri H, Rozbahani M, Jalilian M. Effect of cigarette smoking on coronary arteries and pattern and severity of coronary artery disease: A review. The Journal of International Medical Research. 2021; 49(12):3000605211059893. DOI: 10.1177/03000605211059893
- Behrooz L, Abumoawad A, Rizvi SHM, Hamburg NM. A modern day perspective on smoking in peripheral artery disease. Frontiers in Cardiovascular Medicine. 2023; 10:1154708. DOI: 10.3389/fcvm.2023.1154708
- Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of abdominal aortic aneurysm: A systematic review and meta-analysis of prospective studies. Scientific Reports. 2018; 8(1):14786. DOI: 10.1038/s41598-018-32100-2
- Zieske AW, Takei H, Fallon KB, Strong JP. Smoking and atherosclerosis in youth. Atherosclerosis. 1999; 144(2):403–408. DOI: 10.1016/s0021-9150(98)00326-8
- Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 148(9):e9–e119. DOI: 10.1161/CIR.0000000000001168
- Gidding SS, Liu K, Colangelo LA, Cook NL, Goff DC, et al. Longitudinal determinants of left ventricular mass and geometry: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation Cardiovascular Imaging. 2013; 6(5):769–775. DOI: 10.1161/CIRCIMAGING.112.000450
- N’Gbo N’Gbo Ikazabo R, Bier JC, Jamart J, Mostosi C, Mavroudakis N. Impact on quitting smoking of cognitive impairment in stroke patients. Journal of the Neurological Sciences. 2022; 439(2022):120296. DOI: 10.1016/j.jns.2022.120296
- Benowitz NL, Fraiman JB. Cardiovascular effects of electronic cigarettes. Nature Reviews Cardiology. 2017; 14(8):447–456. DOI: 10.1038/nrcardio.2017.36
- Mulder HA, Patterson JL, Halquist MS, Kosmider L, Turner JBM, Poklis JL, et al. The effect of electronic cigarette user modifications and e-liquid adulteration on the particle size profile of an aerosolized product. Scientific Reports. 2019; 9(1):10221. DOI: 10.1038/s41598-019-46387-2
- Gottlieb MA. Regulation of e-cigarettes in the United States and its role in a youth epidemic. Children. 2019; 6(3):40. DOI: 10.3390/children6030040d
- Cullen KA, Gentzke AS, Sawdey MD, Chang JT, Anic GM, Wang TW, et al. E-cigarette use among youth in the United States, 2019. JAMA. 2019; 322(21):2095–2103. DOI: 10.1001/jama.2019.18387
- Hammond D, Reid JL, Rynard VL, Fong GT, Cummings KM, McNeill A, et al. Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: Repeat national cross sectional surveys. BMJ. 2019; 365:l2219. DOI: 10.1136/bmj.l2219
- Dai H, Leventhal AM. Prevalence of e-cigarette use among adults in the United States, 2014–2018. JAMA. 2019; 322(18):1824–1827. DOI: 10.1001/jama.2019.15331
- Skotsimara G, Antonopoulos AS, Oikonomou E, Siasos G, Ioakeimidis N, Tsalamandris S, et al. Cardiovascular effects of electronic cigarettes: A systematic review and meta-analysis. European Journal of Preventative Cardiology. 2019; 26(11):1219–1228. DOI: 10.1177/2047487319832975
- Wang JB, Olgin JE, Nah G, Vittinghoff E, Cataldo JK, Pletcher MJ, et al. Cigarette and e-cigarette dual use and risk of cardiopulmonary symptoms in the Health eHeart Study. PLoS One. 2018; 13(7):
e0198681e0198681 . DOI: 10.1371/journal.pone.0198681 - Ip M, Diamantakos E, Haptonstall K, Choroomi Y, Moheimani RS, Nguyen KH, et al. Tobacco and electronic cigarettes adversely impact ECG indexes of ventricular repolarization: Implication for sudden death risk. American Journal of Physiology Heart and Circulatory Physiology. 2020; 318(5):H1176–H1184. DOI: 10.1152/ajpheart.00738.2019
- Caporale A, Langham MC, Guo W, Johncola A, Chatterjee S, Wehrli FW. Acute effects of electronic cigarette aerosol inhalation on vascular function detected at quantitative MRI. Radiology. 2019; 293(1):97–106. DOI: 10.1148/radiol.2019190562
- Fetterman JL, Keith RJ, Palmisano JN, McGlasson KL, Weisbrod RM, Majid S, Bastin R, et al. Alterations in vascular function associated with the use of combustible and electronic cigarettes. Journal of the American Heart Association. 2020; 9(9):
e014570 . DOI: 10.1161/JAHA.119.014570 - Klaas FJW, Silja CT, Moritz M, Friedhelm S, Michael R, Klaus D, et al. E-cigarettes and cigarettes worsen peripheral and central hemodynamics as well as arterial stiffness: a randomized, double-blinded pilot study. Vascular Medicine. 2018; 23(5):419–425. DOI: 10.1177/1358863X18779694
- Espinoza-Derout J, Shao XM, Lao CJ, Hasan KM, Rivera JC, Jordan MC, et al. Electronic cigarette use and the risk of cardiovascular diseases. Frontiers in Cardiovascular Medicine. 2022; 9:879726. DOI: 10.3389/fcvm.2022.879726
- Kim SY, Sim S, Choi HG. Active, passive, and electronic cigarette smoking is associated with asthma in adolescents. Scientific Reports. 2017; 7(1):17789. DOI: 10.1038/s41598-017-17958-y
- de Borba AT, Jost RT, Gass R, Nedel FB, Cardoso DM, Pohl HH, et al. The influence of active and passive smoking on the cardiorespiratory fitness of adults. Multidisciplinary Respiratory Medicine. 2014; 9(1):34. DOI: 10.1186/2049-6958-9-34
- Hom S, Chen L, Wang T, Ghebrehiwet B, Yin W, Rubenstein DA. Platelet activation, adhesion, inflammation, and aggregation potential are altered in the presence of electronic cigarette extracts of variable nicotine concentrations. Platelets. 2016; 27(7):694–702. DOI: 10.3109/09537104.2016.1158403
- Rader F, Rashid M, Nguyen TT, Luong E, Kim A, Kim E, et al. E-cigarette use and subclinical cardiac effects. Circulation Research. 2020; 127(12):1566–1567. DOI: 10.1161/CIRCRESAHA.120.316683
- Sifat AE, Vaidya B, Kaisar MA, Cucullo L, Abbruscato TJ. Nicotine and electronic cigarette (e-cig) exposure decreases brain glucose utilization in ischemic stroke. Journal of Neurochemistry. 2018; 147(2):204–221. DOI: 10.1111/jnc.14561
- Raval AP. Nicotine addiction causes unique detrimental effects on women’s brains. Journal of Addictive Diseases. 2011; 30(2):149–158. DOI: 10.1080/10550887.2011.554782
- Moheimani RS, Bhetraratana M, Yin F, Peters KM, Gornbein J, Araujo JA, et al. Increased cardiac sympathetic activity and oxidative stress in habitual electronic cigarette users: Implications for cardiovascular risk. JAMA Cardiology. 2017; 2(3):278–284. DOI: 10.1001/jamacardio.2016.5303
- Basch CH, Mongiovi J, Hillyer GC, MacDonald Z, Basch CE. YouTube™ videos related to e-cigarette safety and related health risks: Implications for preventing and emerging epidemic. Public Health. 2016; 132:57–59. DOI: 10.1016/j.puhe.2015.12.003
- Laranjo L, Lanas F, Sun MC, Chen DA, Hynes L, Imran TF, et al. World Heart Federation roadmap for secondary prevention of cardiovascular disease: 2023 update. Global Heart. 2024; 19(1):8. DOI: 10.5334/gh.1278
- Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: US Department of Health and Human Services; 2008 May. 276 p.
- Rakel RE, Houston T.
Nicotine addiction . In Rakel RE, Rakel DP (Eds.) Textbook of Family Medicine. Philadelphia, PA: Elsevier Health Sciences; 2011. pp. 1105–1122. DOI: 10.1016/B978-1-4377-1160-8.10050-8 - Twyman L, Bonevski B, Paul C, Bryant J. Perceived barriers to smoking cessation in selected vulnerable groups: A systematic review of the qualitative and quantitative literature. BMJ Open. 2014; 4(12):
e006414 . DOI: 10.1136/bmjopen-2014-006414 - Smokefree.gov. Cessation services data [Internet]. National Cancer Institute; [cited 2024 Dec 14]. Available from:
https://smokefree.gov/about-us/cessation-services-data#:~:text=National%20Cessation%20Access%20Portals&text=The%20NNTCQ%20connects%20persons%20interested,%2D855%2DDEJELO%2DYA . - Centers for Disease Control and Prevention. Quitlines and other cessation support resources [Internet]. Centers for Disease Control and Prevention; [updated 2024 May 15; cited 2024 Dec 15]. Available from:
https://www.cdc.gov/tobacco/hcp/patient-care/quitlines-and-other-resources.html . - National Health Service. NHS stop smoking services help you quit [Internet]. National Health Service; [updated 2022 Aug 17; cited 2024 Dec 15]. Available from:
https://www.nhs.uk/live-well/quit-smoking/nhs-stop-smoking-services-help-you-quit/ . - Nides M. Update on pharmacologic options for smoking cessation treatment. The American Journal of Medicine. 2008; 121(4):S20–S31. DOI: 10.1016/j.amjmed.2008.01.016
- Hays JT, McFadden DD, Ebbert JO. Pharmacologic agents for tobacco dependence treatment: 2011 update. Current Atherosclerosis Reports. 2012; 14(1):85–92. DOI: 10.1007/s11883-011-0211-2
- Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: A meta-analysis of randomized controlled trials. CMAJ. 2008; 179(2):135–144. DOI: 10.1503/cmaj.070256
- Stead L, Perera R, Bullen C, Mant D, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. The Cochrane Database of Systematic Reviews. 2012; 11:CD000146. DOI: 10.1002/14651858.CD000146.pub4
- Hughes J, Stead L, Cahill K, Lancaster T. Antidepressants for smoking cessation. The Cochrane Database of Systematic Reviews. 2007; 1:CD00031. DOI: 10.1002/14651858.CD000031.pub3
- Center for Drug Evaluation and Research. FDA Drug Safety Communication: FDA revises description of Mental Health [Internet]. U.S. Food and Drug Administration; 2018 [cited 2025 Feb 15]. Available from:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-description-mental-health-side-effects-stop-smoking . - Evins AE, Benowitz NL, West R, Russ C, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial. Journal of Clinical Psychopharmacology. 2019; 39(2):108–116. DOI: 10.1097/JCP.0000000000001015
- Cahill K, Lindson-Hawley N, Thomas K, Fanshawe T, Lancaster T. Nicotine receptor partial agonists for smoking cessation. The Cochrane Database Systematic Reviews. 2016; 5:CD006103. DOI: 10.1002/14651858.CD006103.pub7
- Center for Drug Evaluation and Research. Safety Review update of Chantix [Internet]. U.S. Food and Drug Administration; 2017 [cited 2025 Feb 15]. Available from:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-chantix-varenicline-and-risk-cardiovascular . - US Food and Drug Administration. FDA drug safety communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease [Internet]. US Food and Drug Administration; [updated 2016 Mar 2; cited 2017 Jul 5]. Available from:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-chantix-varenicline-may-increase-risk-certain-cardiovascular-adverse . - Dehghani P, Habib B, Windle SB, Roy N, Old W, Grondin FR, et al. Smokers and postcessation weight gain after acute coronary syndrome. Journal of the American Heart Association. 2017; 6(4):e004785. DOI: 10.1161/JAHA.116.004785
- Gourlay S, Stead L, Benowitz N. Clonidine for smoking cessation. The Cochrane Database of Systematic Reviews. 2004; 3:CD000058. DOI: 10.1002/14651858.CD000058.pub2
- Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: A review. Nicotine & Tobacco Research. 2005; 7(4):491–499. DOI: 10.1080/14622200500185298
- Tinghino B, Cardellicchio S, Corso F, Cresci C, Pittelli V, Principe R, et al. Cytisine for smoking cessation: A 40-day treatment with an induction period. Tobacco Prevention & Cessation. 2024; 10. DOI: 10.18332/tpc/187556
- Blanch P, Freixa-Pamais R. When are you going to quit smoking? European Society of Cardiology. 2021; 20(6). Available from:
https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-20/when-are-you-going-to-quit-smoking . - European Network for Smoking and Tobacco Prevention. European smoking cessation guidelines and quality standards [Internet]. European Network for Smoking and Tobacco Prevention; [cited 2024 Sept 11]. Available from:
https://ensp.network/european-smoking-cessation-guidelines-and-quality-standards/ . - Rigotti NA, Benowitz NL, Prochaska J, Leischow S, Nides M, Blumenstein B, et al. Cytisinicline for smoking cessation: A randomized clinical trial. JAMA. 2023; 330(2):152–160. DOI: 10.1001/jama.2023.10042
- Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. The Cochrane Database of Systematic Reviews. 2019; 4:CD013308. DOI: 10.1002/14651858.CD013308
- Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, et al. Antidepressants for smoking cessation. The Cochrane Database of Systematic Reviews. 2023; 5(5):CD000031. DOI: 10.1002/14651858.CD000031.pub6
- Cinciripini PM, Green CE, Shete S, Minnix JA, Robinson JD, Cui Y, et al. Smoking cessation after initial treatment failure with varenicline or nicotine replacement: A randomized clinical trial. JAMA. 2024; 331(20):1722–1731. DOI: 10.1001/jama.2024.4183
- Fiore MC. Tobacco use and dependence: A 2011 update of treatments [Internet]. University of Wisconsin School of Medicine and Public Health [updated 2012 Jan 25]. Available from:
https://www.medscape.org/viewarticle/757167 . - Ockene I, Salmoirago-Blotcher E. Varenicline for smoking cessation in patients with coronary heart disease. Circulation. 2010; 121(2):188–90. DOI: 10.1161/CIRCULATIONAHA.109.915546
- Dinno A, Glantz S. Clean indoor air laws immediately reduce heart attacks. Preventive Medicine. 2007; 45(1):9–11. DOI: 10.1016/j.ypmed.2007.03.013
- Barua R, Rigotti N, Benowitz N, Cummings KM, Jazayeri MA, Morris PB, et al. ACC expert consensus decision pathway on tobacco cessation treatment: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. Journal of the American College of Cardiology. 2018; 72(25):3332–3365. DOI: 10.1016/j.jacc.2018.10.027
- Müezzinler A, Mons U, Gellert C, Schöttker B, Jansen E, Kee F, et al. Smoking and all-cause mortality in older adults: Results from the CHANCES consortium. American Journal of Preventative Medicine. 2015; 49(5):e53–e63. DOI: 10.1016/j.amepre.2015.04.004
- Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine & Tobacco Research. 2002; 4(4):433–439. DOI: 10.1080/1462220021000018380.96
- Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: Meta-analysis. BMJ. 2012; 345:
e4439 . DOI: 10.1136/bmj.e4439 - Wada H, Ura S, Satoh-Asahara N, Kitaoka S, Mashiba S, Akao M, et al. α1-antitrypsin low-density-lipoprotein serves as a marker of smoking-specific oxidative stress. Journal of Atherosclerosis and Thrombosis. 2012(1);19:47–58. DOI: 10.5551/jat.9035
- Komiyama M, Wada H, Ura S, Yamakage H, Satoh-Asahara N, Shimada S, et al. The effects of weight gain after smoking cessation on atherogenic α1-antitrypsin low-density lipoprotein. Heart and Vessels. 2015; 30(6):734–739. DOI: 10.1007/s00380-014-0549-9
- Komiyama M, Shimada S, Wada H, Yamakage H, Satoh-Asahara N, Shimatsu A, et al. Time-dependent changes of atherosclerotic LDL complexes after smoking cessation. Journal of Atherosclerosis and Thrombosis. 2016; 23(11):1270–1275. DOI: 10.5551/jat.34280
- Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, et al. Smoking cessation, weight change, type 2 diabetes, and mortality. The New England Journal of Medicine. 2018; 379:623–32. DOI: 10.1056/NEJMoa1803626
- Bush T, Lovejoy J, Javitz H, Torres AJ, Wassum K, Tan MM, et al. Simultaneous vs. sequential treatment for smoking and weight management in tobacco quitlines: 6 and 12 month outcomes from a randomized trial. BMC Public Health. 2018; 18:678–690. DOI: 10.1186/s12889-018-5574-7